Seres Therapeutics Newsroom

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Benzinga02:38 · Ratings

Seres Therapeutics Analyst Ratings

Benzinga02:36 · Ratings

Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)

TipRanksSep 13 19:46 · Ratings

CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10

CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 38.6% and a

Futu NewsSep 13 19:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)

TipRanksSep 13 19:01 · Ratings

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres TherapeuticsSep 13 12:00

Express News | Seres Therapeutics Inc - Ser-155 Shows Well Tolerated Safety Profile, No Serious Adverse Events

BreakingsSep 12 19:00

Express News | Seres Therapeutics Reports Ser-155 Phase 1B Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

BreakingsSep 12 19:00

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

Yahoo FinanceSep 12 19:00

Seres Therapeutics Jumps on Speculation of Nestle Acquisition Offer

Seeking AlphaSep 6 22:49

Watching Seres Therapeutics; Traders Circulate Unconfirmed M&A Blog Comments Suggesting Nestle Has Offered To Acquire The Company For $750M, Or $6-$6.50/Share

BenzingaSep 6 22:43

Seres Therapeutics Shares Halted To The Upside; Up 20.00%

BenzingaSep 6 22:37

2024 Microbiome Market Trends Report Featuring Seres Therapeutics, Rebiotix, IFF (DuPont), Chr. Hansen (Novonesis), Nestle, Probi, Lactobio, Pivot Bio, and LanzaTech - ResearchAndMarkets.com

BusinesswireAug 31 01:46

Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates

TipRanksAug 22 18:55 · Ratings

Bears Are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now

Yahoo FinanceAug 15 21:55

Seres Therapeutics Releases Financial Statements Ahead of Asset Sale

TipRanksAug 15 18:40

Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating

Oppenheimer analyst Jeff Jones maintains $Seres Therapeutics(MCRB.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 37.4% and a total average return of 7.0% over

Futu NewsAug 15 14:32 · Ratings

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesAug 14 21:53

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesAug 14 21:53 · Ratings

Seres Therapeutics (MCRB) Gets a Hold From Oppenheimer

TipRanksAug 14 19:47 · Ratings